



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 7, 2022

Paul Berns  
Chief Executive Officer  
Neumora Therapeutics, Inc.  
65 Grove Street  
Watertown, Massachusetts 02472

**Re: Neumora Therapeutics, Inc.  
Amendment No. 1 to  
Draft Registration Statement on Form S-1  
Submitted December 23, 2021  
CIK No. 0001885522**

Dear Mr. Berns:

We have reviewed your amended draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments.

Amendment No. 1 to Draft Registration Statement on Form S-1 submitted December 23, 2021

NMRA-511, page 138

1. We note your response to our prior comment 9. Please revise your disclosure on page 138 to clarify, if true, that the preclinical and Phase 1a trials for your NMRA-511 candidate were also not powered for statistical significance.

Paul Berns  
Neumora Therapeutics, Inc.  
January 7, 2022  
Page 2

Exhibits

2. We note your disclosure in the footnotes to the exhibit index that certain portions of Exhibits 10.5(a), 10.5(b), 10.5(c), 10.6(a) and 10.6(b) have been redacted. Pursuant to Item 601(b)(10)(iv), please include a statement at the top of the first page of each exhibit stating that certain information has been excluded because it is both not material and the type of information that the registrant treats as private or confidential.

You may contact Eric Atallah at 202-551-3663 or Al Pavot at 202-551-3738 if you have questions regarding comments on the financial statements and related matters. Please contact Jane Park at 202-551-7439 or Laura Crotty at 202-551-7614 with any other questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Phillip Stoup, Esq.